(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(3-((5-propylthiazol-2-yl)methyl)-1H-indol-1-yl)tetrahydro-2H-pyran-3,4,5-triol | 1352714-41-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 吡咯并嘧啶核苷和核苷酸
• 英文名称: (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(3-((5-propylthiazol-2-yl)methyl)-1H-indol-1-yl)tetrahydro-2H-pyran-3,4,5-triol
• 英文别名: (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[3-[(5-propyl-1,3-thiazol-2-yl)methyl]indol-1-yl]oxane-3,4,5-triol
• CAS: 1352714-41-0
• 化学式: C₂₁H₂₆N₂O₅S
• 分子量: 418.514
• InChiKey: IIHMKVIAAADWQT-QNDFHXLGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  136
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same
  申请人：Lee Jinhwa

  公开号：US20130090298A1

  公开（公告）日：2013-04-11

  The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

  本发明涉及一种新型含有噻唑环的化合物，具有对存在于肠和肾中的钠依赖性葡萄糖共转运体2（SGLT2）的抑制活性，以及包含该化合物作为活性成分的制药组合物，用于预防或治疗代谢性疾病，特别是糖尿病。
• US8586550B2
  申请人：——

  公开号：US8586550B2

  公开（公告）日：2013-11-19
• [EN] THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] DÉRIVÉS DE THIAZOLE EN TANT QU'INHIBITEURS DE SGLT2 ET COMPOSITION PHARMACEUTIQUE COMPRENANT CEUX-CI
  申请人：GREEN CROSS CORP

  公开号：WO2011159067A2

  公开（公告）日：2011-12-22

  The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.